Very much attention is normally paid to different sphingolipid pathways for their feasible use within treatment and diagnostics
Very much attention is normally paid to different sphingolipid pathways for their feasible use within treatment and diagnostics. stage of colorectal cancers based on TNM (tumors, nodes, metastasis) classification. We believe the mixed measurement of many ceramide concentrations in plasma Chrysophanic acid (Chrysophanol) might help distinguish early-stage lesions from advanced colorectal cancers and will help create a testing test to identify early colorectal cancers. = 14) had been situated in the rectum, 22.2% (10) within the sigmoid colon, 13.3% (6) in the cecum, and 33.3% (15) in other parts of colon. The average age of patients with the tumor located in several parts of the large intestine was 63.4 3.8 years (range 35C90), 66.2 3.2 years (range 53C87, 70.0 3.0 years (range 48C87), and 70.1 5.9 years (range 45C84), for rectum, sigmoid colon, cecum, and other parts of the colon, respectively. The number of patients in each group according to TNM classification was as follows: 14 (TNM I), 10 (TNM II), 15 (TNM III), 6 (TNM IV). Chrysophanic acid (Chrysophanol) Depending on Chrysophanic acid (Chrysophanol) the progression and stage of the disease (TNM I+II vs. TNM III+IV), the average age was 68.9 2.6 years and 66.1 2.7 years, respectively. The group of patients with well-differentiated cancer (low grade, G1) was the least numerous (2), and the group of patients with moderately differentiated cancer (intermediate grade, G2) was the most numerous (37). Distant metastases were found in 6 patients. Most patients (24) had no evidence of lymph node metastases. Table 1 Demographics and clinical characteristics of colorectal cancer (CRC) patients. 0.05 vs. normal tissue. Simultaneously, of the remaining sphingolipids, the highest content (distinct than in normal tissue) was demonstrated for C24:0-Cer (6.55 pmol/mg vs. 4.77 pmol/mg; 0.0013) and Sph (6.38 vs. 2.37, 0.001). Sphingolipid contents in tumor and normal intestinal tissue were compared. CRC tissue also showed an increased amount of S1P Rabbit Polyclonal to SFXN4 (0.05 vs. 0.02; 0.00013), SPA (1.48 vs. 0.72; 0.0003), and C14:0-Cer (1.60 vs. 1.15; 0.0031), compared to normal intestinal tissue. At the same time, tumor tissue was found to have a significantly lower C18:0-Cer content (3.09 vs. 4.07; 0.0039) and C20:0-Cer content (0.88 vs. 1.33; 0.00001) than in normal colorectal tissue, Table 2. We examined the relationship of sphingolipid levels in CRC tissue on tumor localization at four different parts of the large intestine. The relationships were complex and ambiguous. But the amount of total ceramides was the lowest in sigmoid and cecum tumors (121.69 21.36 and 128.11 22.82 respectively) and the largest in rectal tumors (182.17 12.19); the difference in these cases was statistically significant (= 0.016). In addition, the level of remaining sphingolipid species Chrysophanic acid (Chrysophanol) was the highest (S1P 0.08 0.02, Sph 9.26 2.57, SPA 2.40 0.70) in one location (cecum) and the lowest in the sigmoid colon (S1P 0.03 0.004) or in Chrysophanic acid (Chrysophanol) other parts of the large intestine, except for the rectum, sigmoid colon, and the cecum (Sph, SPA). The difference was statistically significant only for S1P (= 0.03). A different sphingolipids profile was found in normal intestinal tissues; of the remaining sphingolipids, the highest content was demonstrated for C18:0-Cer (4.07 pmol/mg) and C24:0-Cer (4.77 pmol/mg). 3.4. Concentration of Sphingolipids in the Plasma The plasma profile of sphingolipids was different than in tissues. By far the highest concentration in the plasma was found for C24:0-Cer (2502.77 pmol/mL; 47.4% of total ceramide) and C24:1-Cer (1474.22 pmol/mL; 27.9% of total ceramide)..